Fed. Circ. Affirms PTAB Ax Of Indivior's Suboxone Patent
A split Federal Circuit panel on Wednesday affirmed a Patent Trial and Appeal Board decision invalidating most claims of an Indivior patent on its opioid addiction treatment Suboxone, finding that the...To view the full article, register now.
Already a subscriber? Click here to view full article